$731 Million is the total value of SPHERA FUNDS MANAGEMENT LTD.'s 90 reported holdings in Q2 2019. The portfolio turnover from Q1 2019 to Q2 2019 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CRVS | Exit | CORVUS PHARMACEUTICALS INC | $0 | – | -83,607 | -100.0% | -0.03% | – |
| Exit | NICE SYS INCnote 1.250% 1/1 | $0 | – | -250,000 | -100.0% | -0.03% | – | |
| SBPH | Exit | SPRING BK PHARMACEUTICALS IN | $0 | – | -51,015 | -100.0% | -0.05% | – |
| CNST | Exit | CONSTELLATION PHARMCETICLS I | $0 | – | -40,162 | -100.0% | -0.05% | – |
| MGTX | Exit | MEIRAGTX HOLDINGS PLC | $0 | – | -36,159 | -100.0% | -0.06% | – |
| CHRS | Exit | COHERUS BIOSCIENCES INC | $0 | – | -75,600 | -100.0% | -0.09% | – |
| ACER | Exit | ACER THERAPEUTICS INC | $0 | – | -50,000 | -100.0% | -0.11% | – |
| TOCA | Exit | TOCAGEN INC | $0 | – | -120,000 | -100.0% | -0.12% | – |
| GILT | Exit | GILAT SATELLITE NETWORKS LTD | $0 | – | -176,406 | -100.0% | -0.14% | – |
| CTMX | Exit | CYTOMX THERAPEUTICS INC | $0 | – | -183,151 | -100.0% | -0.18% | – |
| ARYA | Exit | ARYA SCIENCES ACQUISITION CO | $0 | – | -200,000 | -100.0% | -0.19% | – |
| DCPH | Exit | DECIPHERA PHARMACEUTICALS IN | $0 | – | -115,033 | -100.0% | -0.24% | – |
| OSMT | Exit | OSMOTICA PHARMACEUTICALS PLC | $0 | – | -864,006 | -100.0% | -0.28% | – |
| GLYC | Exit | GLYCOMIMETICS INC | $0 | – | -311,013 | -100.0% | -0.35% | – |
| KDMN | Exit | KADMON HLDGS INC | $0 | – | -1,490,000 | -100.0% | -0.36% | – |
| LOGC | Exit | LOGICBIO THERAPEUTICS INC | $0 | – | -417,625 | -100.0% | -0.38% | – |
| MGNX | Exit | MACROGENICS INC | $0 | – | -235,000 | -100.0% | -0.39% | – |
| GBT | Exit | GLOBAL BLOOD THERAPEUTICS IN | $0 | – | -80,000 | -100.0% | -0.39% | – |
| FIXX | Exit | HOMOLOGY MEDICINES INC | $0 | – | -161,000 | -100.0% | -0.41% | – |
| BHVN | Exit | BIOHAVEN PHARMACTL HLDG CO L | $0 | – | -88,015 | -100.0% | -0.41% | – |
| MLNX | Exit | MELLANOX TECHNOLOGIES LTDput | $0 | – | -38,500 | -100.0% | -0.42% | – |
| CBAY | Exit | CYMABAY THERAPEUTICS INC | $0 | – | -345,535 | -100.0% | -0.42% | – |
| MHK | Exit | MOHAWK INDS INC | $0 | – | -37,000 | -100.0% | -0.43% | – |
| SBBP | Exit | STRONGBRIDGE BIOPHARMA PLC | $0 | – | -951,600 | -100.0% | -0.43% | – |
| ANAB | Exit | ANAPTYSBIO INC | $0 | – | -70,000 | -100.0% | -0.47% | – |
| XENE | Exit | XENON PHARMACEUTICALS INC | $0 | – | -533,655 | -100.0% | -0.50% | – |
| GOOGL | Exit | ALPHABET INCcap stk cl a | $0 | – | -5,000 | -100.0% | -0.54% | – |
| CARA | Exit | CARA THERAPEUTICS INC | $0 | – | -303,930 | -100.0% | -0.54% | – |
| IMMU | Exit | IMMUNOMEDICS INC | $0 | – | -326,660 | -100.0% | -0.57% | – |
| AXGT | Exit | AXOVANT SCIENCES LTD | $0 | – | -5,108,333 | -100.0% | -0.62% | – |
| BIIB | Exit | BIOGEN INC | $0 | – | -30,000 | -100.0% | -0.65% | – |
| AERI | Exit | AERIE PHARMACEUTICALS INC | $0 | – | -150,000 | -100.0% | -0.65% | – |
| CLLS | Exit | CELLECTIS S Asponsored ads | $0 | – | -447,970 | -100.0% | -0.75% | – |
| PTCT | Exit | PTC THERAPEUTICS INC | $0 | – | -220,500 | -100.0% | -0.76% | – |
| NVS | Exit | NOVARTIS A Gsponsored adr | $0 | – | -100,000 | -100.0% | -0.88% | – |
| BIIB | Exit | BIOGEN INCput | $0 | – | -60,000 | -100.0% | -1.30% | – |
| NVO | Exit | NOVO-NORDISK A Sadr | $0 | – | -400,000 | -100.0% | -1.91% | – |
| CELG | Exit | CELGENE CORPput | $0 | – | -300,000 | -100.0% | -2.58% | – |
| GILD | Exit | GILEAD SCIENCES INC | $0 | – | -480,000 | -100.0% | -2.85% | – |
| XBI | Exit | SPDR SERIES TRUSTput | $0 | – | -3,335,000 | -100.0% | -27.56% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEVA PHARMACEUTICAL-SP ADR | 36 | Q3 2023 | 8.4% |
| MERCK & CO INC NEW | 35 | Q3 2023 | 8.4% |
| NICE Systems Ltd | 27 | Q3 2023 | 4.4% |
| BIOGEN INC | 26 | Q3 2023 | 6.7% |
| AMICUS THERAPEUTICS INC | 26 | Q2 2022 | 4.3% |
| PFIZER INC | 25 | Q3 2023 | 9.2% |
| SAREPTA THERAPEUTICS INC | 25 | Q3 2023 | 3.2% |
| JOHNSON & JOHNSON | 24 | Q3 2023 | 8.0% |
| UNIQURE NV | 23 | Q3 2023 | 1.2% |
| SYNDAX PHARMACEUTICALS INC | 22 | Q3 2023 | 3.9% |
View SPHERA FUNDS MANAGEMENT LTD.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Cyclacel Pharmaceuticals, Inc. | February 06, 2023 | 250,000 | 2.0% |
| Altimmune, Inc. | February 14, 2022 | 1,244,241 | 3.1% |
| Allot Ltd. | February 16, 2021 | 1,129,054 | 3.2% |
| Larimar Therapeutics, Inc. | February 16, 2021 | ? | ? |
| Neos Therapeutics, Inc. | February 16, 2021 | ? | ? |
| Orgenesis Inc. | February 16, 2021 | 525,216 | 0.0% |
| Sio Gene Therapies Inc. | February 16, 2021 | ? | ? |
| X4 Pharmaceuticals, Inc | February 16, 2021 | 250,000 | 0.0% |
| Axovant Gene Therapies Ltd. | February 25, 2020 | 2,931,017 | 8.0% |
| Axovant Gene Therapies Ltd. | February 11, 2020 | 398,540 | 1.8% |
View SPHERA FUNDS MANAGEMENT LTD.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR/A | 2024-02-15 |
| 13F-HR | 2024-02-14 |
| SC 13G | 2024-02-08 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-10 |
View SPHERA FUNDS MANAGEMENT LTD.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.